COMMODORE CAPITAL
SEC RegisteredInvesting In Innovative Companies To Improve Patients' Lives
About the firm
Commodore Capital invests in innovative biopharmaceutical companies, believing the industry is in the early stages of a major innovation cycle driven by novel therapeutic modalities such as genetic medicines and cellular therapies. The firm focuses on smaller biopharmaceutical companies where much of today's innovation is occurring, striving to be good partners as these companies work to bring safe and effective new medicines to patients around the world.
Firm Focus
Client segments reported on the firm's SEC Form ADV — applies to all advisors at the firm.
Areas of expertise
Services
Who they serve
| Client segment | Clients | Assets managed |
|---|---|---|
| Pension/Profit Sharing Plans | 3 | $2.4B |
0 total clients reported on Form ADV.
Leadership
Office locations
Regulatory & compliance
| Asset tier | Annual rate |
|---|---|
| Management Fee Range Low | 1.50% |
| Management Fee Range High | 1.75% |
Data as of March 31, 2026 · Source: SEC IAPD & FINRA BrokerCheck
Contact Information
This profile was compiled and published by AdvisorFinder as editorial content using publicly available information from the SEC's IAPD database and FINRA BrokerCheck. COMMODORE CAPITAL has not reviewed, approved, or endorsed this profile and is not responsible for its accuracy. Regulatory records change over time — always verify the current record directly on the SEC or FINRA websites before making any decision.
BrokerCheck data is used subject to the FINRA BrokerCheck Terms of Use. Found something inaccurate? Report inaccurate data and we will correct any error we introduced. Errors in the underlying BrokerCheck record itself are referred to FINRA, which maintains that record.
Find the right advisor for you
Take the free 3-minute assessment to get matched with advisors who fit your goals.
Get Matched